Literature DB >> 9757942

The CLIP-substituted invariant chain efficiently targets an antigenic peptide to HLA class II pathway in L cells.

S Fujii1, S Senju, Y Z Chen, M Ando, S Matsushita, Y Nishimura.   

Abstract

The presentation of antigenic peptides by major histocompatibility complex (MHC) class II to CD4+ T cells is crucial to initiate immune responses. We developed a new system for delivery of an antigenic peptide to the MHC class II pathway, using the invariant chain (Ii). We designed a mutated human p33-form Ii, CLIP-substituted Ii, in which streptococcal M12p55-68 (RDLEQAYNELSGEA) was substituted for CLIP (class II associated invariant chain peptide). We examined the peptide presenting function of this construct, in comparison with the previously reported C-terminal fused Ii, in which a cathepsin cleavage site and M12p54-68 was ligated to the C-terminus of Ii. Mouse L cell transfectants expressing either of these two mutated Ii along with HLA-DR4 could process and present M12p55-68 to the peptide specific and DR4-restricted CD4+ T cell clone. CLIP-substituted Ii was much more efficient in antigen presentation than was the C-terminal fused Ii. Similar to the wild-type Ii, the CLIP-substituted Ii was associated intracellularly with DR4 molecules. These results indicate that the peptide substituted for CLIP of Ii p33 bound to the groove of DR molecules in the same manner as CLIP and it was preferentially presented to the CD4+ T cell clone in the absence of HLA-DM molecules. This system may prove useful for immunotherapy with DNA vaccines or for construction of an antigen presenting cell library with diverse peptides.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9757942     DOI: 10.1016/s0198-8859(98)00058-5

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  10 in total

Review 1.  Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells.

Authors:  Shaw-Wei D Tsen; Augustine H Paik; Chien-Fu Hung; T-C Wu
Journal:  Expert Rev Vaccines       Date:  2007-04       Impact factor: 5.217

2.  DNA vaccines encoding Ii-PADRE generates potent PADRE-specific CD4+ T-cell immune responses and enhances vaccine potency.

Authors:  Chien-Fu Hung; Ya-Chea Tsai; Liangmei He; T-C Wu
Journal:  Mol Ther       Date:  2007-03-13       Impact factor: 11.454

3.  Induction of protective immunity to Listeria monocytogenes by immunization with plasmid DNA expressing a helper T-cell epitope that replaces the class II-associated invariant chain peptide of the invariant chain.

Authors:  Toshi Nagata; Taiki Aoshi; Mina Suzuki; Masato Uchijima; Yeung-Hyen Kim; Zhibo Yang; Yukio Koide
Journal:  Infect Immun       Date:  2002-05       Impact factor: 3.441

Review 4.  Immunotherapy with pluripotent stem cell-derived dendritic cells.

Authors:  Satoru Senju; Yusuke Matsunaga; Satoshi Fukushima; Shinya Hirata; Yutaka Motomura; Daiki Fukuma; Hidetake Matsuyoshi; Yasuharu Nishimura
Journal:  Semin Immunopathol       Date:  2011-04-05       Impact factor: 9.623

Review 5.  Pluripotent stem cells as source of dendritic cells for immune therapy.

Authors:  Satoru Senju; Shinya Hirata; Yutaka Motomura; Daiki Fukuma; Yusuke Matsunaga; Satoshi Fukushima; Hidetake Matsuyoshi; Yasuharu Nishimura
Journal:  Int J Hematol       Date:  2010-02-13       Impact factor: 2.490

6.  Tolerance induction using lentiviral gene delivery delays onset and severity of collagen II arthritis.

Authors:  Inger Gjertsson; Karen L Laurie; James Devitt; Steven J Howe; Adrian J Thrasher; Rikard Holmdahl; Kenth Gustafsson
Journal:  Mol Ther       Date:  2009-01-27       Impact factor: 11.454

7.  Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4(+) T cells.

Authors:  R F Wang; X Wang; S A Rosenberg
Journal:  J Exp Med       Date:  1999-05-17       Impact factor: 14.307

8.  Suppression of Th1-mediated autoimmunity by embryonic stem cell-derived dendritic cells.

Authors:  Tokunori Ikeda; Shinya Hirata; Koutaro Takamatsu; Miwa Haruta; Hirotake Tsukamoto; Takaaki Ito; Makoto Uchino; Yukio Ando; Seiho Nagafuchi; Yasuharu Nishimura; Satoru Senju
Journal:  PLoS One       Date:  2014-12-18       Impact factor: 3.240

9.  Antigen-delivery through invariant chain (CD74) boosts CD8 and CD4 T cell immunity.

Authors:  Nadia Mensali; Amalie Grenov; Niladri Bhusan Pati; Pierre Dillard; Marit Renée Myhre; Gustav Gaudernack; Gunnar Kvalheim; Else Marit Inderberg; Oddmund Bakke; Sébastien Wälchli
Journal:  Oncoimmunology       Date:  2019-01-11       Impact factor: 8.110

Review 10.  Designs of Antigen Structure and Composition for Improved Protein-Based Vaccine Efficacy.

Authors:  Kyle Saylor; Frank Gillam; Taylor Lohneis; Chenming Zhang
Journal:  Front Immunol       Date:  2020-02-24       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.